**Mayo – Israel Pilot and R&D Program Call for Proposals**

**May 26th – September 19th, 2022**

The *Israel Innovation Authority* (the Authority) and *Mayo Clinic* (MC) invite interested Israeli companies to submit applications for research & development projects or pilot solutions in the healthcare-related technology field with MC.

This call is open both to joint proposal for cooperation in R&D activities with MC, and for pilot projects for companies that wish to pilot, scale-up and adapt their new innovative technologies and solutions.

MC and the authority are seeking to advance healthcare by helping Israeli companies get the evidence and assistance they need to fine-tune their development and to enter and be successful in the United States’ healthcare market.

MC would serve as a real-world living laboratory for the Israeli companies, where MC clinical and research experts would work with Israeli startups to test and improve existing processes, services, or products; or to apply a new process to health care for the first time.

The goal of this collaboration is to accelerate the availability of medical innovations to the public, introduce Israeli healthcare technology to the U.S., and advance the development and deployment of discoveries for the benefit of patients everywhere**.**

The Authority provides resources to aid technology advancement for Israeli companies.

**Mayo Clinic** is ranked as No. 1 hospital overall and top-ranked in twelve specialties. Complex care often requires medical experts from more than one specialty. With world-class experts working together across specialties, MC gives patients the unparalleled care they deserve.

**The health themes of interest to MC include** digital, device, therapeutic or diagnostic technologies. MC has broad research and clinical interests and interested co-development projects in which it can add value to the company.

**Deadline for submissions: 19/09/2022**

**What support do the Authority and Mayo Clinic offer?**

Successful Israeli applicant companies will receive funding from the authority and may negotiate for in-kind services from MC under an appropriate agreement.

The authority can support R&D performing companies, registered and operating in Israel, with a grant of up to 50% of the approved Pilot or R&D Expenses Budget, according to its regulations and procedures.

* Research institutions as subcontractors to eligible companies.

When a project eventually results in sales of a product, service, or process, the financial support must be repaid in royalties to the *Israel Innovation Authority* according to its regulations. In general, royalties are paid at rates beginning at 3% of sales, depending on various criteria. Royalties are payable until 100% of the amount of the grant has been repaid with interest as provided in the applicable regulations. If the project does not result in sales, no repayment is required.

An appropriate agreement between successful applicant companies and MC will need to be signed before project initiation.

**Requirements**

Cooperation proposals should be in line with the following requirements:

1. The participation of at least one company from each country is mandatory. Research institutes and other companies may participate as partners or subcontractors in the cooperation project, respecting the financing rules of each country.
2. The proposal should result in the development of an improved or new product or process with industrial application intended for commercialization in domestic and/or global markets, including proof of concept projects for technology-based solutions.
3. The new product / process should be innovative, have relevant market potential, technological risk and add value to the economies of both countries.
4. The project should demonstrate adequate balance and complementarity between the two partners in relation to the R&D phases.
5. The project should present a clear competitive advantage and differentiated value proposition as a result of cooperation between the participants of the two countries (increase of knowledge base, access to R&D infrastructure, new fields of application, for example).
6. Companies should present a strategy which, given their technological, commercial, and financial aspects, demonstrates their potential to introduce the new product / process into the markets of both countries and/or third countries.
7. Partners in the project must agree in advance on the allocation of intellectual property rights (IP) between companies, as well as the marketing strategy. This agreement should reflect a proportional allocation and a fair return for both partners in relation to their respective investments.
8. In a pilot project proposal, the IP rights will stay in the hands of the Israeli partner
9. Partners in Israel and in Brazil should be able to implement the project and finance their respective shares.
10. Any partnership whose cooperative R&D project is consistent with the above criteria may present it in this Call, in accordance with applicable national laws, rules, regulations and procedures.

**Process and Timeline**

|  |  |
| --- | --- |
| Program launch | 26/05/2022 |
| Agreement signing and submission to the Authority | 19/09/2022 |

**Contacts**

|  |  |
| --- | --- |
| **Mayo Clinic** Mayo-Israeli Start-up InitiativeEmail: mayoclinicventures@mayo.edu | **Israel Innovation Authority**Alan HofmanBusiness Development Manager+972-3-715-7987Alan.hofman@innovationisrael.org.il |